Organogenesis Holdings Inc

NASDAQ:ORGOUnited States

Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types. Sports Medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for management of open wounds in the surgical setting.

Contact Information

Headquarters

85 Dan RdCANTON, MA, United States 02021-2810

Phone

781-575-0775

Fax

302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer

Gary Gillheeney

Chief Financial Officer

David Francisco

Chief Operating Officer

Patrick Bilbo

Chief Administrative and Legal Officer

Lori Freedman

Vice President - Health Policy

Antonio Montecalvo